Quest Partners LLC Grows Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Quest Partners LLC increased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 36,146.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,334 shares of the biopharmaceutical company's stock after buying an additional 37,231 shares during the period. Quest Partners LLC's holdings in Catalyst Pharmaceuticals were worth $742,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company's stock worth $127,212,000 after purchasing an additional 860,244 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Catalyst Pharmaceuticals by 9.6% during the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company's stock worth $46,479,000 after buying an additional 263,099 shares during the period. Pacer Advisors Inc. increased its stake in shares of Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company's stock worth $45,968,000 after buying an additional 2,965,310 shares during the period. Janus Henderson Group PLC increased its stake in shares of Catalyst Pharmaceuticals by 139.5% during the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company's stock worth $43,445,000 after buying an additional 1,587,794 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Catalyst Pharmaceuticals by 15.2% during the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company's stock worth $33,702,000 after buying an additional 287,300 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ CPRX traded up $0.36 during mid-day trading on Friday, hitting $21.48. 863,612 shares of the company were exchanged, compared to its average volume of 1,190,937. The stock has a 50 day simple moving average of $21.10 and a 200-day simple moving average of $18.49. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.00 and a 1-year high of $24.27. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of 17.95, a price-to-earnings-growth ratio of 3.29 and a beta of 0.75.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Truist Financial increased their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, November 11th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Monday. They issued an "overweight" rating and a $35.00 price target on the stock. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 9th. Finally, Citigroup increased their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a "buy" rating in a report on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.